ストックスクリーナーアプリを入手
8.495
2.59%
0.205
前日終値:
$8.29
開ける：
$8.185
24時間の取引高:
1.50M
Relative Volume:
0.28
時価総額：
$2.16B
収益：
$874.84M
当期純損益:
$263.86M
株価収益率:
7.0609
EPS:
1.2031
ネットキャッシュフロー:
$327.41M
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
-4.87%
6か月 パフォーマンス:
+19.79%
1年 パフォーマンス:
-19.69%
1日の値動き範囲:
$8.11
$8.51
1週間の範囲:
$8.11
$8.97
52週間の値動き範囲:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
名前
Biocryst Pharmaceuticals Inc
セクター
電話
919-859-1302
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.505 | 2.11B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
15.94 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.275 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.90 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.97 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
573.27 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-18 | 再開されました | Evercore ISI | Outperform |
| 2025-10-15 | 再開されました | TD Cowen | Buy |
| 2025-10-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 開始されました | Wedbush | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-09-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-02-22 | アップグレード | Needham | Hold → Buy |
| 2022-11-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-04-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-08-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Overweight |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-05-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-15 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 再開されました | Piper Jaffray | Overweight |
| 2018-08-08 | 再開されました | JP Morgan | Overweight |
| 2018-07-17 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 開始されました | Seaport Global Securities | Neutral |
| 2018-01-02 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 開始されました | Barclays | Equal Weight |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-09-06 | アップグレード | Jefferies | Hold → Buy |
| 2017-02-16 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-08-12 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | FBR Capital | Outperform |
| 2016-02-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-02-09 | ダウングレード | Needham | Buy → Hold |
すべてを表示
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
BCRX (NASDAQ) Form 144: Affiliate plans resale of 11,180 shares - Stock Titan
BioCryst’s SWOT analysis: rare disease stock eyes growth path By Investing.com - Investing.com Nigeria
BioCryst’s SWOT analysis: rare disease stock eyes growth path - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth beyond single product - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability - Investing.com UK
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path - Investing.com
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
Responsive Playbooks and the BCRX Inflection - Stock Traders Daily
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX) - Sahm
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Biocryst (BCRX) CLO sells 62,500 shares in pre-set 10b5-1 trade - Stock Titan
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case - Sahm
BioCryst Pharmaceuticals stock (US09058V1035): Shares surge 9% after earnings - AD HOC NEWS
BCRX Jumps As Price Target Hike Caps Busy Catalyst Week - StocksToTrade
62,500-share resale registered by BCRX insider (NASDAQ: BCRX) - Stock Titan
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 - The Manila Times
BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference - Quiver Quantitative
BioCryst to Present New Real-World Evidence Underscoring - GlobeNewswire
Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition - PR Newswire
Study: Kids with rare swelling disorder log 3x outpatient visits vs peers - Stock Titan
BioCryst Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BioCryst Q1 2026 slides: dual HAE strategy targets $1.8B revenue - Investing.com Canada
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up By Investing.com - Investing.com South Africa
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed? - Yahoo Finance
State Street (NASDAQ: BCRX) holds 4.9% of BioCryst, 12.2M shares - Stock Titan
Influenza Therapeutics Market to Reach USD 12.94 Billion by 2033 - openPR.com
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal - Yahoo Finance
European patients gain future access to HAE drug navenibart in $300M deal - Angioedema News
Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes - Sahm
Number of shareholders of BioCryst Pharmaceuticals, Inc. – FWB:BO1 - TradingView
These analysts revise their forecasts on BioCryst Pharma after Q1 earnings - MSN
BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
BioCryst (BCRX) Q1 2026 Earnings Transcript - AOL.com
BCRX Adjusts FY26 Revenue Outlook with Key Estimates - GuruFocus
BioCryst (BCRX) Reports Q1 Revenue Growth Amid Significant Loss - GuruFocus
Biocryst Pharmaceuticals Inc (BCRX) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.89%
大文字化:
|
ボリューム (24 時間):